Alzheimer’s Disease

The value of plasma p-tau181 as a screening and diagnostic tool for Alzheimer’s disease

The future of SAGE-718 in Alzheimer’s disease treatment

Understanding the effect of other diseases on blood biomarker levels in AD

The impact of TKIs on miRNA expression in the treatment of AD

Use of machine learning in Alzheimer’s disease

APOEε4 carriership combined with Aβ positivity for AD clinical trial enrichment

Potential value of p-tau181 and NfL for clinical trial pre-screening

Therapeutic potential of omega-3 supplementation in slowing cognitive decline for APOE4 carriers

Biomarkers for early detection of Alzheimer’s disease: microRNAs

Insights into the upcoming LIGHTWAVE trial using SAGE-718 to treat patients with MCI and early AD

The COCOA Trial: can multimodal lifestyle interventions treat AD?

Systemic inflammation and reduced cerebral Aβ clearance triggered by pancreatic amylin

New mechanisms to treat Alzheimer’s disease by targeting the NMDA pathway

Long-term transdermal nicotine for the treatment of mild cognitive impairment

The role of p53 in the pathogenesis of Alzheimer’s disease

The PreventE4 study: testing omega-3 supplementation in APOE4 carriers before the onset of dementia